| __timestamp | BioMarin Pharmaceutical Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 751040000 | 24890000000 |
| Thursday, January 1, 2015 | 889895000 | 32639000000 |
| Friday, January 1, 2016 | 1116854000 | 30390000000 |
| Sunday, January 1, 2017 | 1313646000 | 26107000000 |
| Monday, January 1, 2018 | 1491212000 | 22127000000 |
| Tuesday, January 1, 2019 | 1704048000 | 22449000000 |
| Wednesday, January 1, 2020 | 1860455000 | 24689000000 |
| Friday, January 1, 2021 | 1846275000 | 27305000000 |
| Saturday, January 1, 2022 | 2096039000 | 27281000000 |
| Sunday, January 1, 2023 | 2419226000 | 27116000000 |
| Monday, January 1, 2024 | 2853915000 | 28754000000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, Gilead Sciences, Inc. and BioMarin Pharmaceutical Inc. have emerged as key players. Over the past decade, Gilead Sciences has consistently outperformed BioMarin in terms of annual revenue. From 2014 to 2023, Gilead's revenue peaked in 2015, reaching approximately $32.6 billion, while BioMarin's highest revenue was around $2.4 billion in 2023. Despite the significant difference in scale, BioMarin has shown a commendable growth trajectory, with its revenue more than tripling over the period. This comparison highlights the diverse strategies and market focuses of these two companies. Gilead's dominance is evident, but BioMarin's steady growth underscores its potential in niche markets. As the biotech industry continues to innovate, these companies' financial performances offer valuable insights into their strategic directions and market positions.
Breaking Down Revenue Trends: Amgen Inc. vs Gilead Sciences, Inc.
Bristol-Myers Squibb Company and Gilead Sciences, Inc.: A Comprehensive Revenue Analysis
Gilead Sciences, Inc. and Bio-Techne Corporation: A Comprehensive Revenue Analysis
Gilead Sciences, Inc. and Celldex Therapeutics, Inc.: A Comprehensive Revenue Analysis
Zoetis Inc. vs BioMarin Pharmaceutical Inc.: Annual Revenue Growth Compared
Breaking Down Revenue Trends: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc.: Who Leads in Yearly Revenue?
BioMarin Pharmaceutical Inc. and Grifols, S.A.: A Comprehensive Revenue Analysis
BioMarin Pharmaceutical Inc. vs PTC Therapeutics, Inc.: Annual Revenue Growth Compared
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Annual Revenue Growth Compared
BioMarin Pharmaceutical Inc. vs Amphastar Pharmaceuticals, Inc.: Annual Revenue Growth Compared
Comparing Revenue Performance: BioMarin Pharmaceutical Inc. or Viridian Therapeutics, Inc.?